5-Oxo-5-<4-methoxy-phenyl>-valeriansaeure-amid | 91641-28-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-Oxo-5-<4-methoxy-phenyl>-valeriansaeure-amid
• 英文别名: 5-Oxo-5-(4-methoxy-phenyl)-valeriansaeure-amid；5-(4-Methoxyphenyl)-5-oxopentanamide
• CAS: 91641-28-0
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: PYJRWRYWHLWYAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-(4-甲氧基苯基)-5-氧代戊酸 在 吡啶 、 氨 、 甲基磺酰氯 作用下， 反应 1.0h， 生成 5-Oxo-5-<4-methoxy-phenyl>-valeriansaeure-amid
  参考文献：
  名称：

  (Phenylmethoxy)phenyl derivatives of w-oxo- and w-tetrazolylalkanoic acids and related tetrazoles. Synthesis and evaluation as leukotriene D4 receptor antagonists

  摘要：

  Two series of (phenylmethoxy)phenyl compounds derived from the structure of LY163443 were synthesized and evaluated as leukotriene D4 receptor antagonists. In the OMEGA-[(phenylmethoxy)phenyl]-OMEGA-oxoalkanoic acid series, 5-[4-[(4-acetyl-2-ethyl-3-hydroxyphenyl)methoxy]phenyl]-3,3-dimethyl-5-oxopentanoic acid (8) was the most potent antagonist of LTD4-induced contractions of guinea pig ileum (pK(B) of 7.60) and LTD4 pressor response in pithed rats (ED50 of 1.4 mg/kg iv). Replacing the carboxylic acid function with 5-tetrazole gave slightly more potent compounds. In the OMEGA-[5-[[(phenylmethoxy)phenyl]alkyl]tetrazolyl]alkanoic acid series, replacing the carboxylic acid with 5-tetrazole gave compounds that were equally effective in the guinea pig ileum but more potent in vivo against the LTD4 pressor response in rat. The pK(B) value in the guinea pig ileum for 1-[2-hydroxy-3-propyl-4-[[4-[[2-[3-(1H-tetrazol-5-yl)propyl]-2H-tetrazol-5-yl]methyl]phenoxy]methyl]phenyl]ethanone (25) was 7.87 and the ED50 for antagonism of the LTD4 pressor response was 4.0 mg/kg iv. The sodium salts of 8 (9) and 25 (26) given by the iv route of administration antagonized LTD4-induced cardiovascular alterations in anesthetized rat and LTD4-induced bronchoconstriction in guinea pig in a dose-dependent manner. Oral activity was also demonstrated against the LTD4-induced bronchoconstriction in guinea pig.

  DOI：

  10.1021/jm00113a014

文献信息

• Carbacyclin analogues
  申请人：THE UPJOHN COMPANY

  公开号：EP0159784A1

  公开（公告）日：1985-10-30

  A compound of the formula and intermediates useful in preparing same.

  一种化合物的公式及其制备过程中有用的中间体。
• 9-Substituted carbacyclin analogues
  申请人：THE UPJOHN COMPANY

  公开号：EP0086611A1

  公开（公告）日：1983-08-24

  Novel compounds of the following general formula: wherein R is -CN; -CH2X wherein X is chloro or bromo; -CH=CH2; -CHO; -CH20H; -C≡CH; -C≡C-CF3; -C≡C-CnH2nCH3 wherein n is zero, one, 2 or 3; cis-CH=CHCnH2nCH3 or trans -CH=CHCnH2nCH3 wherein n is zero, one, 2 or 3; -CH=C(X')2 wherein X' is fluoro, chloro, or bromo; cis-CH=CHX' or trans-CH=CHX' wherein X' is fluoro, chloro, or bromo;-C≡C-C≡CR1 wherein R1 is hydrogen, methyl, or ethyl; -C≡COR2 wherein R2 is methyl or ethyl; and intermediates for their preparation.

  以下通式的新型化合物： 其中 R 是 -CN；- X，其中 X 是氯或溴；-CH=CH2；-CHO；- 0H；-C≡CH；-C≡C-CF3；-C≡C-CnH2nCH3，其中 n 是零、1、2 或 3；顺式-CH=CHCnH2nCH3 或反式-CH=CHCnH2nCH3，其中 n 是零、1、2 或 3；顺式-CH=C(X')2，其中 X'为氟、氯或溴；顺式-CH=CHX'或反式-CH=CHX'，其中 X'为氟、氯或溴；-C≡C-C≡CR1，其中 R1 为氢、甲基或乙基；-C≡COR2，其中 R2 为甲基或乙基；以及用于制备它们的中间体。
• Benzopyrans
  申请人：THE UPJOHN COMPANY

  公开号：EP0088619A2

  公开（公告）日：1983-09-14

  Compounds of the formula wherein the 11 and 12-substituents correspond to prosta- groups and 12-sidechams, respectively, and the corresponds to prostagiandin C atoms 1 to 4 (Q a carboxyl function or derivative thereof). These can nave pharmacological activity. Novel inter- are also disclosed.

  这些化合物可以具有药理活性。 此外，还公开了新的互作化合物。
• The therapeutic use of prostaglandins
  申请人：THE UPJOHN COMPANY

  公开号：EP0153858A2

  公开（公告）日：1985-09-04

  The use of a PGE-like prostaglandin for the manufacture of a medicament for the treatment or prevention of a human suffering from or prone to acute respiratory distress syndrome or multiple vital organ damage, and for the treatment of a human suffering from shock, trauma, sepsis or any combination thereof.

  使用 PGE 类前列腺素制造治疗或预防急性呼吸窘迫综合征或多重要器官损伤的药物，以及治疗休克、创伤、败血症或其任何组合的药物。
• 9-Substituted carbacyclins
  申请人：THE UPJOHN COMPANY

  公开号：EP0092352B1

  公开（公告）日：1986-07-02